J&J said it found no immediate procedure-related causes from the atrial fibrillation therapy but that risks can escalate if a ...

Johnson & Johnson MedTech announced that it intends to resume the rollout of its Varipulse platform in the U.S. after a ...

To predict arrhythmic risk in carriers of filamin C truncating variants, a novel risk predictive model was developed based on ...

(Reuters) -Johnson & Johnson said on Friday it resumed the limited market release of its Varipulse heart device in the United ...

J.P. Morgan analysts said the findings of J&J’s investigation “could significantly hinder the product’s rollout in the U.S.

The instructions for use have been updated to address issues that led to a greater risk of neurovascular events in an early ...

Nearly six weeks after Johnson & Johnson paused the U.S. external evaluation of its Varipulse pulsed field ablation catheter ...

"Johnson & Johnson to resume market release of Varipulse catheter in US" was originally created and published by Medical ...

A recent pause in U.S. sales of Varipulse is hampering the company’s bid to catch up in one of the industry’s fastest-growing ...

Johnson & Johnson will resume the limited market release of VARIPULSE in the United States after a comprehensive ...

Johnson & Johnson is relaunching sales of a promising heart-rhythm device after a safety scare, but with a new warning for doctors that analysts say could hamper its market potential ...

Feb 14 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Friday it resumed the limited market release of its Varipulse heart device in the United States after an investigation found the ...